阿托伐他汀对急性冠脉综合征患者血清MMP-9及IL-18的影响  

Effect of atorvastatin on serum levels of matrix metalloproteinase-9 and interleukin-18 in patients with acute coronary syndrome

作　　者：胡晓辉[1] 孟皓波[2] 张世维 

机构地区：[1]武警内蒙古总队医院首长保健科,呼和浩特010040 [2]武警内蒙古总队医院内二科,呼和浩特010040 [3]武警内蒙古总队后勤部卫生处,呼和浩特010051

出　　处：《武警医学》2014年第9期905-907,共3页Medical Journal of the Chinese People's Armed Police Force

摘　　要：目的探讨阿托伐他汀对急性冠脉综合征(acute coronary syndrome,ACS)患者血清基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)、白介素-18(interleukin-18,IL-18)水平的影响。方法将ACS患者60例随机分为阿托伐他汀组(阿托伐他汀20 mg/d,连续用药14 d)和对照组(除未用阿托伐他汀外,余治疗同阿托伐他汀组)。药物治疗前及治疗14 d后检测血清MMP-9、IL-18水平。结果阿托伐他汀组治疗后MMP-9及IL-18[分别是(295±110)mg/L和(399±115)pg/ml]与治疗前[分别是(368±97)mg/L和(471±105)pg/ml]比较有下降,差异均有统计学意义(P<0.05);阿托伐他汀组治疗后MMP-9及IL-18水平均明显低于同期对照组[分别是(358±95)mg/L和(466±109)pg/ml],差异有统计学意义(P<0.05)。结论阿托伐他汀可降低ACS患者血清MMP-9、IL-18水平,抑制斑块内炎性反应,促进斑块的稳定性。Objective To investigate the effect of atorvastatin on plasma MMP-9 and IL-18 in patients with acute coronary syn-drome （ ACS ） .Methods Sixty patients with ACS were randomly divided into treatment group （ taking atorvastatin 20 mg/d for 14 days）, control group （no atorvastatin, other treatments were similar to treatment group ）.Before drug therapy and after 14 days, MMP-9 and IL-18 levels in serum were measured .Results Compared with pre-treatment, the levels of MMP-9 and IL-18 in treatment group were decreased [（295 ±110）mg/L vs（358 ±95）mg/L;（399 ±115）pg/ml vs（471 ±105）pg/ml ,respectively],these differences were statistically significant （P〈0.05）.Moreover, the levels of MMP-9 and IL-18 in treatment group were significantly lower than those in control group [（358 ±95）mg/L,（466 ±109）pg/ml, respectively], these differences were statistically significant （P〈0.05）.Conclu-sions Atorvastatin can decrease serum MMP-9 and IL-18 levels in patients with ACS , which contributes to inhibit plaque inflammation , to advance the stability of plaque .Early intensive atorvastatin treatment may yield more significant benefits to the patients with ACS .

关 键 词：急性冠脉综合征 阿托伐他汀 基质金属蛋白酶-9 白介素-18 

分 类 号：R541.4[医药卫生—心血管疾病]